查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1320026

骨質疏鬆藥物市場：按藥物類型、給藥途徑和用途- 全球預測 2023-2030

Osteoporosis Drugs Market by Drug Type, Route of Administration, Application - Cumulative Impact of COVID-19, Russia Ukraine Conflict, and High Inflation - Global Forecast 2023-2030
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

全球骨質疏鬆藥物市場預計將以5.56%的年複合成長率大幅成長，2023年達到83.2471億美元，2030年達到121.9261億美元。

FPNV定位矩陣

FPNV定位矩陣對於評估全球骨質疏鬆藥物市場至關重要。透過檢驗業務策略和產品滿意度等關鍵指標，它可以對供應商進行全面評估，使用戶能夠根據自己的特定需求做出明智的資訊。這種進階分析將供應商分為四個像限，並取得了不同程度的成功：前沿 (F)、探路者 (P)、利基 (N) 和重要 (V)。

市佔率分析

市場佔有率分析可以深入了解供應商在特定市場領域的當前地位。比較供應商對總收入、基本客群和其他關鍵指標的貢獻，可以幫助公司更好地了解他們在爭奪市場佔有率時的表現以及面臨的情況。該分析還揭示了特定行業的競爭程度、累積和合併的優勢以及研究基準年的合併特徵。

本報告提供了以下幾點見解：

1. 市場滲透率：提供有關主要企業所服務的市場的全面資訊。

2. 市場開發：提供有關利潤豐厚的新興市場的詳細資訊，並分析其在成熟市場的滲透率。

3. 市場多元化：提供有關新產品發布、未開發領域、最新發展和投資的詳細資訊。

4.市場趨勢：全面了解COVID-19、俄羅斯-烏克蘭衝突和高通膨的累積影響。

5.競爭評估與資訊：對主要企業的市場佔有率、策略、產品、認證、法規狀況、專利狀況、製造能力等進行綜合評估。

6. 產品開發與創新：提供對未來技術、研發活動和突破性產品開發的見解。

本報告回答了以下問題：

1.全球骨質疏鬆藥物市場規模及預測為何？

2.在預測期內，COVID-19對全球骨質疏鬆症治療藥物市場的阻礙因素與影響為何？

3.在預測期內，全球骨質疏鬆藥物市場需要投資哪些產品/細分市場/應用/領域？

4.全球骨質疏鬆藥物市場的競爭策略為何？

5.全球骨質疏鬆藥物市場的技術趨勢和法律規範是什麼？

6.全球骨質疏鬆藥物市場主要廠商的市佔率為何？

7. 哪些型態和策略性措施被認為適合進入全球骨質疏鬆藥物市場？

目錄

第1章 前言

第2章 調查方法

第3章 執行摘要

第4章 市場概況

第5章 市場洞察

  • 市場動態
    • 促進因素
      • 老年人口的增加和生活方式的改變影響骨骼健康
      • 提高停經後婦女骨質疏鬆症照護意識和骨質疏鬆症發生率
    • 抑制因素
      • 對骨質疏鬆症藥物專利到期日的擔憂
    • 機會
      • 醫療機構的新產品開發和研究活動
      • 各機構研究經費快速增加
    • 任務
      • 與骨質疏鬆症藥物相關的副作用，如噁心、胃灼熱和潰瘍
  • 市場趨勢
  • COVID-19 的累積影響
  • 俄羅斯-烏克蘭衝突的累積影響
  • 高通膨的累積效應
  • 波特五力分析
  • 價值鍊和關鍵路徑分析
  • 法律規範
  • 客戶客製化

第6章 依藥物類型分類的骨質疏鬆症治療藥物市場

  • 雙磷酸鹽
  • 降鈣素
  • 副甲狀腺素治療
  • 配體抑制劑排名
  • 選擇性雌激素抑制劑調節劑

第7章 骨質疏鬆症治療藥物市場：依給藥途徑

  • 可注射的
  • 口服

第8章 骨質疏鬆症治療藥物市場：依用途

  • 原發性骨質疏鬆症
  • 續發性骨質疏鬆症

第9章 北美及南美骨質疏鬆藥物市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章 亞太骨質疏鬆藥物市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章歐洲、中東和非洲骨質疏鬆藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭形勢

  • FPNV定位矩陣
  • 市佔率分析：主要企業
  • 競爭情境分析：主要企業
    • 併購
    • 合約、合作和夥伴關係
    • 新產品發布和功能增強
    • 投資、資金籌措
    • 獎項/獎勵/擴展

第13章上市公司名單

第14章附錄

  • 討論指南
  • 關於許可證和定價
Product Code: MRR-AD36CD898103

The Global Osteoporosis Drugs Market is forecasted to grow significantly, with a projected USD 8,324.71 million in 2023 at a CAGR of 5.56% and expected to reach a staggering USD 12,192.61 million by 2030.

The Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and High Inflation is expected to have significant long-term effects on the Global Osteoporosis Drugs Market. The ongoing research considers the changes in consumer behavior, supply chain disruptions, and government interventions caused by the pandemic. Similarly, the report considers the ongoing political and economic uncertainty in Eastern Europe caused by the Russia-Ukraine Conflict and its potential implications for demand-supply balances, pressure on pricing variants, and import/export and trading. Additionally, the report addresses the impact of High Inflation on the global economy and details fiscal policies measuring and reducing its effects on demand, supply, cash flow, and currency exchange.

Market Segmentation & Coverage:

This research report categorizes the Global Osteoporosis Drugs Market in order to forecast the revenues and analyze trends in each of following sub-markets:

Based on Drug Type, market is studied across Bisphosphonates, Calcitonin, Parathyroid Hormone Therapy, Rank Ligand Inhibitors, and Selective Estrogen Inhibitors Modulator. The Bisphosphonates commanded largest market share of 31.09% in 2022, followed by Calcitonin.

Based on Route of Administration, market is studied across Injectable and Oral. The Oral commanded largest market share of 62.86% in 2022, followed by Injectable.

Based on Application, market is studied across Primary Osteoporosis and Secondary Osteoporosis. The Primary Osteoporosis commanded largest market share of 61.34% in 2022, followed by Secondary Osteoporosis.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Europe, Middle East & Africa commanded largest market share of 39.56% in 2022, followed by Americas.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the Global Osteoporosis Drugs Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in a particular market space. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation

5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players

6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Osteoporosis Drugs Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global Osteoporosis Drugs Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Osteoporosis Drugs Market?

4. What is the competitive strategic window for opportunities in the Global Osteoporosis Drugs Market?

5. What are the technology trends and regulatory frameworks in the Global Osteoporosis Drugs Market?

6. What is the market share of the leading vendors in the Global Osteoporosis Drugs Market?

7. What modes and strategic moves are considered suitable for entering the Global Osteoporosis Drugs Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Osteoporosis Drugs Market, by Drug Type, 2022 vs 2030
  • 4.3. Osteoporosis Drugs Market, by Route of Administration, 2022 vs 2030
  • 4.4. Osteoporosis Drugs Market, by Application, 2022 vs 2030
  • 4.5. Osteoporosis Drugs Market, by Region, 2022 vs 2030

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising elderly population coupled with changing lifestyle habits impacting bone health
      • 5.1.1.2. Increasing awareness of osteoporosis care and incidence of osteoporosis in postmenopausal women
    • 5.1.2. Restraints
      • 5.1.2.1. Concerns over patent expiration of osteoporosis drugs
    • 5.1.3. Opportunities
      • 5.1.3.1. Emerging product development and research activities in healthcare organizations
      • 5.1.3.2. Proliferation in the research funding from various organizations
    • 5.1.4. Challenges
      • 5.1.4.1. Side effects such as nausea, heartburn, and ulcers associated with osteoporosis drugs
  • 5.2. Market Trends
  • 5.3. Cumulative Impact of COVID-19
  • 5.4. Cumulative Impact of Russia-Ukraine Conflict
  • 5.5. Cumulative Impact of High Inflation
  • 5.6. Porter's Five Forces Analysis
    • 5.6.1. Threat of New Entrants
    • 5.6.2. Threat of Substitutes
    • 5.6.3. Bargaining Power of Customers
    • 5.6.4. Bargaining Power of Suppliers
    • 5.6.5. Industry Rivalry
  • 5.7. Value Chain & Critical Path Analysis
  • 5.8. Regulatory Framework
  • 5.9. Client Customization

6. Osteoporosis Drugs Market, by Drug Type

  • 6.1. Introduction
  • 6.2. Bisphosphonates
  • 6.3. Calcitonin
  • 6.4. Parathyroid Hormone Therapy
  • 6.5. Rank Ligand Inhibitors
  • 6.6. Selective Estrogen Inhibitors Modulator

7. Osteoporosis Drugs Market, by Route of Administration

  • 7.1. Introduction
  • 7.2. Injectable
  • 7.3. Oral

8. Osteoporosis Drugs Market, by Application

  • 8.1. Introduction
  • 8.2. Primary Osteoporosis
  • 8.3. Secondary Osteoporosis

9. Americas Osteoporosis Drugs Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Osteoporosis Drugs Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Osteoporosis Drugs Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. FPNV Positioning Matrix
  • 12.2. Market Share Analysis, By Key Player
  • 12.3. Competitive Scenario Analysis, By Key Player
    • 12.3.1. Merger & Acquisition
      • 12.3.1.1. Amgen to Acquire Horizon for USD 27.8 Billion, Expanding Rare Disease Pipeline.
      • 12.3.1.2. Tymlos maker Radius Health sells itself to investment firms for USD 890 Million..
    • 12.3.2. Agreement, Collaboration, & Partnership
      • 12.3.2.1. WHO and ESCEO announce collaborative agreement to benefit global osteoporosis and fracture prevention.
      • 12.3.2.2. Akums Drugs ties up with Microcore Research to manufacture NESM supplements.
      • 12.3.2.3. Lupin signs agreement with I'rom for clinical trials and marketing of post-menopause drug in Japan.
    • 12.3.3. New Product Launch & Enhancement
      • 12.3.3.1. Chugai and Towa Launch Edirol Tablet for Osteoporosis Treatment
    • 12.3.4. Investment & Funding
      • 12.3.4.1. New funding for osteoporosis research announced
    • 12.3.5. Award, Recognition, & Expansion
      • 12.3.5.1. FDA Clears Tymlos for Osteoporosis in Men
      • 12.3.5.2. EVENITY (romosozumab) Receives Positive CHMP Opinion for the Treatment of Severe Osteoporosis in Postmenopausal Women at High Risk of Fracture
      • 12.3.5.3. Pharmanovia expands its footprint in China with the acquisition of Rocaltrol from Roche

13. List of Company Mentioned

14. Appendix

  • 14.1. Discussion Guide
  • 14.2. License & Pricing

LIST OF FIGURES

  • FIGURE 1. OSTEOPOROSIS DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. OSTEOPOROSIS DRUGS MARKET SIZE, 2022 VS 2030
  • FIGURE 3. OSTEOPOROSIS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2022 VS 2030 (%)
  • FIGURE 5. OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2022 VS 2030 (%)
  • FIGURE 6. OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2022 VS 2030 (%)
  • FIGURE 7. OSTEOPOROSIS DRUGS MARKET SIZE, BY REGION, 2022 VS 2030 (%)
  • FIGURE 8. OSTEOPOROSIS DRUGS MARKET DYNAMICS
  • FIGURE 9. OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 10. OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 11. OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS OSTEOPOROSIS DRUGS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 13. UNITED STATES OSTEOPOROSIS DRUGS MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC OSTEOPOROSIS DRUGS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 15. EUROPE, MIDDLE EAST & AFRICA OSTEOPOROSIS DRUGS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 16. OSTEOPOROSIS DRUGS MARKET, FPNV POSITIONING MATRIX, 2022
  • FIGURE 17. OSTEOPOROSIS DRUGS MARKET SHARE, BY KEY PLAYER, 2022

LIST OF TABLES

  • TABLE 1. OSTEOPOROSIS DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
  • TABLE 3. OSTEOPOROSIS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 5. OSTEOPOROSIS DRUGS MARKET SIZE, BY BISPHOSPHONATES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 6. OSTEOPOROSIS DRUGS MARKET SIZE, BY CALCITONIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. OSTEOPOROSIS DRUGS MARKET SIZE, BY PARATHYROID HORMONE THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. OSTEOPOROSIS DRUGS MARKET SIZE, BY RANK LIGAND INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. OSTEOPOROSIS DRUGS MARKET SIZE, BY SELECTIVE ESTROGEN INHIBITORS MODULATOR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 11. OSTEOPOROSIS DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. OSTEOPOROSIS DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 14. OSTEOPOROSIS DRUGS MARKET SIZE, BY PRIMARY OSTEOPOROSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. OSTEOPOROSIS DRUGS MARKET SIZE, BY SECONDARY OSTEOPOROSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. AMERICAS OSTEOPOROSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 17. AMERICAS OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 18. AMERICAS OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 20. ARGENTINA OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 21. ARGENTINA OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 22. ARGENTINA OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 23. BRAZIL OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 24. BRAZIL OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 25. BRAZIL OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 26. CANADA OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. CANADA OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 28. CANADA OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 29. MEXICO OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. MEXICO OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 31. MEXICO OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 32. UNITED STATES OSTEOPOROSIS DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 33. UNITED STATES OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. UNITED STATES OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 35. UNITED STATES OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 36. ASIA-PACIFIC OSTEOPOROSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 37. ASIA-PACIFIC OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. ASIA-PACIFIC OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 39. ASIA-PACIFIC OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 40. AUSTRALIA OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. AUSTRALIA OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 42. AUSTRALIA OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 43. CHINA OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. CHINA OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 45. CHINA OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 46. INDIA OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. INDIA OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 48. INDIA OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 49. INDONESIA OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. INDONESIA OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 51. INDONESIA OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 52. JAPAN OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. JAPAN OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 54. JAPAN OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 55. MALAYSIA OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. MALAYSIA OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 57. MALAYSIA OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 58. PHILIPPINES OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. PHILIPPINES OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 60. PHILIPPINES OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 61. SINGAPORE OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. SINGAPORE OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 63. SINGAPORE OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 64. SOUTH KOREA OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. SOUTH KOREA OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 66. SOUTH KOREA OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 67. TAIWAN OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. TAIWAN OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 69. TAIWAN OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 70. THAILAND OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. THAILAND OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 72. THAILAND OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 73. VIETNAM OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. VIETNAM OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 75. VIETNAM OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 76. EUROPE, MIDDLE EAST & AFRICA OSTEOPOROSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 77. EUROPE, MIDDLE EAST & AFRICA OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 80. DENMARK OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. DENMARK OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 82. DENMARK OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 83. EGYPT OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. EGYPT OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 85. EGYPT OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 86. FINLAND OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. FINLAND OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 88. FINLAND OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 89. FRANCE OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. FRANCE OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 91. FRANCE OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 92. GERMANY OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. GERMANY OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 94. GERMANY OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 95. ISRAEL OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. ISRAEL OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 97. ISRAEL OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 98. ITALY OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. ITALY OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 100. ITALY OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 101. NETHERLANDS OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. NETHERLANDS OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 103. NETHERLANDS OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 104. NIGERIA OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. NIGERIA OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 106. NIGERIA OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 107. NORWAY OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. NORWAY OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 109. NORWAY OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 110. POLAND OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. POLAND OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 112. POLAND OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 113. QATAR OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. QATAR OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 115. QATAR OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 116. RUSSIA OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. RUSSIA OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 118. RUSSIA OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 119. SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 121. SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 122. SOUTH AFRICA OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. SOUTH AFRICA OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 124. SOUTH AFRICA OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 125. SPAIN OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. SPAIN OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 127. SPAIN OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 128. SWEDEN OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. SWEDEN OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 130. SWEDEN OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 131. SWITZERLAND OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. SWITZERLAND OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 133. SWITZERLAND OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 134. TURKEY OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. TURKEY OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 136. TURKEY OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 137. UNITED ARAB EMIRATES OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. UNITED ARAB EMIRATES OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 139. UNITED ARAB EMIRATES OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED KINGDOM OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED KINGDOM OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED KINGDOM OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 143. OSTEOPOROSIS DRUGS MARKET, FPNV POSITIONING MATRIX, 2022
  • TABLE 144. OSTEOPOROSIS DRUGS MARKET SHARE, BY KEY PLAYER, 2022
  • TABLE 145. OSTEOPOROSIS DRUGS MARKET LICENSE & PRICING